RBF Capital’s Solid Biosciences SLDB Stock Holding History

RBF Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,460	Closed	-$73K	–	576
2022 Q3	$73K	Hold	10,460	–	–	0.01%	507
2022 Q2	$97K	Buy	+10,460	New	+$109K	0.01%	502

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RBF Capital's SLDB Position: Q4 2022 in Review

RBF Capital sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 10,460 shares — an estimated $73K sold.

RBF Capital first reported a position in SLDB in Q2 2022 and held it in 2 quarters. The position peaked at $97K in Q2 2022. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

RBF Capital reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
RBF Capital sold 10,460 Solid Biosciences shares in Q4 2022, an estimated $73K.
RBF Capital first reported a position in Solid Biosciences in Q2 2022 and held it in 2 quarters.
RBF Capital's Solid Biosciences position peaked at $97K in Q2 2022.
35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on RBF Capital's 13F filing for Q4 2022, filed 14 Feb 2023.